Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0007222 (
cardiovascular disease
)
65,817
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The aim of this study is to assess the association of two polymorphisms, the
cartilage intermediate layer protein 2
(
CILP2
) G/T and angiotensin converting enzyme (ACE) I/D, with blood pressure and anthropometrical and biochemical parameters related to the development of
cardiovascular disease
. The entire study sample comprised 341 women ranging in age from 39 to 65 years. The
CILP2
genotypes were determined by PCR-RFLP and the ACE genotypes by PCR. The Bonferroni pairwise comparisons showed the effect of the
CILP2
genotype on high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), apoB-to-apoA1 ratio, the total cholesterol (TC)-to-HDL-C ratio, non-HDL-C, and the LDL-C-to-HDL-C ratio (P < 0.05). Here, higher mean levels of HDL-C and lower mean levels of the remaining above mentioned lipid parameters were registered in the GT/TT genotype carriers than in GG carriers. Statistically significant association was identified between the ACE genotype and the following parameters: TC, LDL-C, and non-HDL-C (P < 0.05). The II genotype can lower serum level of TC (B = 0.40), LDL-C (B = 0.37), and non-HDL-C levels. The results of this study suggest that the minor T allele of
CILP2
gene and I allele of ACE gene have a protective effect against elevated serum lipid and lipoprotein levels.
...
PMID:Association of CILP2 and ACE gene polymorphisms with cardiovascular risk factors in Slovak midlife women. 2435 Feb 79